4-amino-1-tert-butyl-3-(m-benzyloxyphenyl)pyrazolo<3,4-d>pyrimidine | 221243-93-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-amino-1-tert-butyl-3-(m-benzyloxyphenyl)pyrazolo<3,4-d>pyrimidine
• 英文别名: 1-tert-butyl-3-(3-(benzyloxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine；4-amino-1-(tert-butyl)-3-(m-benzyloxyphenyl)pyrazolo[3,4-d]pyrimidine；4-amino-1-tert-butyl-3-(m-benzyloxyphenyl)pyrazolo[3,4-d]pyrimidine；1-tert-butyl-3-(3-phenylmethoxyphenyl)pyrazolo[3,4-d]pyrimidin-4-amine
• CAS: 221243-93-2
• 化学式: C₂₂H₂₃N₅O
• 分子量: 373.458
• InChiKey: VIRRZTDSKWFONP-UHFFFAOYSA-N

物化性质

• 沸点：
  581.1±45.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  78.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-amino-1-tert-butyl-3-(m-benzyloxyphenyl)pyrazolo<3,4-d>pyrimidine 在 盐酸 、 甲酸 、 水 作用下， 反应 0.5h， 生成 3-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenol 、 3-(3-(benzyloxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  参考文献：
  名称：

  Kinase antagonists

  摘要：

  本发明提供了一种新型化合物，它们是 PI3 激酶、PI3 激酶和酪氨酸激酶、PI3 激酶和 mTOR，或者 PI3 激酶、mTOR 和酪氨酸激酶的拮抗剂。

  公开号：

  US20070293516A1
• 作为产物：
  描述：

  3-苯甲氧基苯甲酰氯 在 sodium hydride 、 碳酸氢钠 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 水 为溶剂， 反应 11.0h， 生成 4-amino-1-tert-butyl-3-(m-benzyloxyphenyl)pyrazolo<3,4-d>pyrimidine
  参考文献：
  名称：

  Optimizing Small Molecule Inhibitors of Calcium-Dependent Protein Kinase 1 to Prevent Infection by Toxoplasma gondii

  摘要：

  Toxoplasma gondii is sensitive to bulky pyrazolo [3,4-d] pyrimidine (PP) inhibitors due to the presence of a Gly gatekeeper in the essential calcium dependent protein kinase 1 (CDPK1). Here we synthesized a number of new derivatives of 3-methyl-benzyl-PP (3-MB-PP, or 1). The potency of PP analogues in inhibiting CDPK1 enzyme activity in vitro (low nM IC50 values) and blocking parasite growth in host cell monolayers in vivo (low mu M EC50 values) were highly correlated and occurred in a CDPK1-specific manner. Chemical modification of the PP scaffold to increase half-life in the presence of microsomes in vitro led to identification of compounds with enhanced stability while retaining activity. Several of these more potent compounds were able to prevent lethal infection with T. gondii in the mouse model. Collectively, the strategies outlined here provide a route for development of more effective compounds for treatment of toxoplasmosis and perhaps related parasitic diseases.

  DOI：

  10.1021/jm4001314

文献信息

• KINASE ANTAGONISTS
  申请人：KNIGHT ZACHARY A.

  公开号：US20100009963A1

  公开（公告）日：2010-01-14

  The present invention provides novel compounds that are antagonists of PI3 kinase, PI3 kinase and tyrosine kinase, PI3 kinase and mTOR, or PI33 kinase, mTOR and tyrosine kinase.

  本发明提供了一些新型化合物，它们是PI3激酶、PI3激酶和酪氨酸激酶、PI3激酶和mTOR、或PI3激酶、mTOR和酪氨酸激酶的拮抗剂。
• Kinase Antagonists
  申请人：Knight Zachary A.

  公开号：US20110301144A1

  公开（公告）日：2011-12-08

  The present invention provides novel compounds that are antagonists of PI3 kinase, PI3 kinase and tyrosine kinase, PI3 kinase and mTOR, or PI33 kinase, mTOR and tyrosine kinase.

  本发明提供了一种新型化合物，它们是PI3激酶、PI3激酶和酪氨酸激酶、PI3激酶和mTOR或PI33激酶、mTOR和酪氨酸激酶的拮抗剂。
• Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists
  申请人：The Regents of the University of California

  公开号：US07585868B2

  公开（公告）日：2009-09-08

  The present invention provides novel compounds that can be used as antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR. The present invention also provides methods of using the compounds for treating various disease conditions. The compounds include those having the formula: wherein the R1, R2 and R36 are as defined herein.

  本发明提供了一种新颖的化合物，可用作脂质激酶（如PI3激酶，蛋白酪氨酸激酶和/或蛋白丝氨酸/苏氨酸激酶，如mTOR）的拮抗剂。本发明还提供了使用这些化合物治疗各种疾病的方法。这些化合物包括具有以下式的化合物：其中R1，R2和R36如本文所定义。
• Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents
  申请人：Knight Zachary A.

  公开号：US08642604B2

  公开（公告）日：2014-02-04

  The present invention provides novel compounds that are antagonists of PI3 kinase, PI3 kinase and tyrosine kinase, PI3 kinase and mTOR, or PI33 kinase, mTOR and tyrosine kinase.

  本发明提供了一种新型化合物，其为PI3激酶、PI3激酶和酪氨酸激酶、PI3激酶和mTOR或PI33激酶、mTOR和酪氨酸激酶的拮抗剂。
• MODULATION OF PROTEIN TRAFFICKING
  申请人：Bulawa Christine Ellen

  公开号：US20100331297A1

  公开（公告）日：2010-12-30

  Compounds and compositions are provided for treatment or amelioration of one or more disorders characterized by defects in protein trafficking. A method of treating a disorder characterized by impaired protein trafficking includes administering to a subject or contacting a cell with a compound of Formula I: [formula here] or pharmaceutically acceptable salts or derivatives thereof.

  本发明提供用于治疗或改善由蛋白质运输缺陷所特征的一个或多个疾病的化合物和组合物。一种治疗由蛋白质运输受损所特征的疾病的方法包括向受试者施用或与细胞接触化合物I的药物或其药学上可接受的盐或衍生物。[公式在此]